Skip to main content
Fig. 1 | Biological Research

Fig. 1

From: Neuroprotective effects of the PPARβ/δ antagonist GSK0660 in in vitro and in vivo Parkinson’s disease models

Fig. 1

(A) MTS assay of differentiated SH-SY5Y treated with different concentration of 6-OHDA for 24 h. (B) MTS assay of cells treated with 25 µM 6-OHDA and 25 µM 6-OHDA + 0.2µM GSK0660. (C) Delta Cell index (DCI) evaluation in control and treated cells. (D) Live-cell IncuCyte cytotoxicity assay in cell treated with 25 µM 6-OHDA, 25 µM 6-OHDA + 0.2µM GSK0660 and 0.2µM GSK0660 alone. A representative figure for CTR and treated cells at 0 and 24 h is shown (n = 3). Scale bar: 200 μm. *** p < 0.0005; ** p < 0.005; * p < 0.05 vs. control (CTR). +p < 0.05 vs. 6-OHDA (n = 3)

Back to article page